Latest / Interprofessional Critical Care Network (ICCN) Podcast / Let the kidney set the target: renal Doppler to set MAP targets in sepsis
Transcript
- 0:00SPEAKER_01: The order says keep the mean arterial pressure at 65 or above.
- 0:03SPEAKER_01: Is 65 enough for this patient's kidneys?
- 0:06SPEAKER_01: A trial in 274 adults with sepsis let a bedside Doppler reading
- 0:09SPEAKER_01: of the kidney pick each patient's pressure target.
- 0:12SPEAKER_01: The kidney signal improved.
- 0:14SPEAKER_01: Survival did not clearly follow.
- 0:16SPEAKER_01: This is the ICCN Daily Brief for Monday, November 16, 2026.
- 0:21SPEAKER_00: If you follow the show, each morning's brief is waiting for you.
- 0:24SPEAKER_00: Today's article is about personalizing the MAP target in septic shock and about why
- 0:29SPEAKER_00: the comparison arm matters as much as the idea.
- 0:35SPEAKER_01: Set the background.
- 0:36SPEAKER_01: Why not aim higher for everyone?
- 0:39SPEAKER_00: Because that has been tried.
- 0:41SPEAKER_00: In the OPT-PRESS trial, 518 patients aged 65 or older
- 0:45SPEAKER_00: with septic shock were randomized to a map of 80 to 85 or 65 to 70.
- 0:52SPEAKER_00: The trial stopped early.
- 0:53SPEAKER_00: 90-day mortality was 39.3% with the high target and 28.6% with the standard one.
- 1:01SPEAKER_01: So what did the new trial do instead?
- 1:03SPEAKER_00: It is called RRI MAP Sepsis by Wang and colleagues.
- 1:08SPEAKER_00: It ran at one teaching hospital in Shijijang,
- 1:12SPEAKER_00: China from March 2022 to January 2024.
- 1:16SPEAKER_00: It enrolled adults with sepsis who still needed norepinephrine to hold a MAP of 65
- 1:22SPEAKER_00: after initial resuscitation.
- 1:25SPEAKER_00: 274 were randomized, 138 to titration, and 136 to conventional care.
- 1:32SPEAKER_00: How did the titration work?
- 1:34SPEAKER_00: It used the renal resistive index,
- 1:36SPEAKER_00: a Doppler ratio that tracks how hard the kidney's arterial tree pushes back
- 1:40SPEAKER_00: against each heartbeat.
- 1:42SPEAKER_00: Norepinephrine went up or down by 0.02 micrograms per kilogram per minute at a time.
- 1:48SPEAKER_00: After 5 to 10 minutes of stability, the index was measured three times and averaged.
- 1:54SPEAKER_00: The team kept stepping until the index fell and then climbed again, tracing a V.
- 1:59SPEAKER_00: The map at the bottom became that patient's target,
- 2:02SPEAKER_00: and nurses kept the pressure within 5 millimeters of mercury of it for 12 hours.
- 2:07SPEAKER_01: And the comparison arm?
- 2:09SPEAKER_00: Conventional care aimed for 65 to 70 millimeters of mercury in patients
- 2:13SPEAKER_00: without hypertension, and 80 to 85 millimeters of mercury in those with it.
- 2:18SPEAKER_00: In practice, that arm averaged a map of about 80.
- 2:22SPEAKER_01: The numbers.
- 2:23SPEAKER_01: Titration first.
- 2:24SPEAKER_01: Conventional second.
- 2:26SPEAKER_00: The V showed up in 98.5% of titrated patients.
- 2:31SPEAKER_00: Right after titration, the index was 0.61 in the titration arm and 0.67
- 2:38SPEAKER_00: in the conventional arm, p less than 0.001.
- 2:42SPEAKER_00: It was still lower at the 24 and 48 hour checks,
- 2:46SPEAKER_00: even though average map did not differ between the groups.
- 2:49SPEAKER_00: And the primary outcome?
- 2:51SPEAKER_00: Death from any cause at 28 days.
- 2:54SPEAKER_00: 25 of 138 titrated patients had died
- 2:57SPEAKER_00: and 36 of 136 conventional patients.
- 3:01SPEAKER_00: The risk ratio, titration versus conventional,
- 3:04SPEAKER_00: was 0.69 with a 95% confidence interval
- 3:09SPEAKER_00: from 0.44 to 1.08 and p equals 0.11.
- 3:14SPEAKER_00: Mortality did not reach significance.
- 3:17SPEAKER_00: Kidney outcomes?
- 3:18SPEAKER_00: Mixed.
- 3:20SPEAKER_00: Continuous renal replacement therapy within 28 days was used
- 3:24SPEAKER_00: in 20 versus 31 patients.
- 3:27SPEAKER_00: P equals 0.087.
- 3:30SPEAKER_00: Stage 3 injury was less common with titration, 13.4% versus 24.6%.
- 3:37SPEAKER_00: But the overall spread of stages did not differ significantly.
- 3:41SPEAKER_01: What did reach significance?
- 3:43SPEAKER_00: To secondary outcomes, days free of continuous renal replacement therapy had
- 3:48SPEAKER_00: a median of 28 in both arms, P equals 0.012.
- 3:53SPEAKER_00: Ventilator-free days were 19 versus 16, P equals 0.04.
- 3:58SPEAKER_00: After a Bonferroni correction across the secondary outcomes,
- 4:02SPEAKER_00: only the renal replacement result held with an adjusted P of 0.048.
- 4:09SPEAKER_01: Anything on safety?
- 4:10SPEAKER_00: New arrhythmias in the first week occurred in 56 of 134 titrated patients versus 74
- 4:17SPEAKER_00: of 134 conventional patients.
- 4:19SPEAKER_00: Norepinephrine doses did not differ over the first three days.
- 4:23SPEAKER_00: Why arrhythmias fell when drug exposure did not is unexplained.
- 4:27SPEAKER_00: And the authors call for confirmation.
- 4:29SPEAKER_01: What does this trial not show?
- 4:31SPEAKER_00: That kidney-guided titration lowers mortality.
- 4:35SPEAKER_00: The article notes that the confidence interval runs from a large benefit to a small harm.
- 4:40SPEAKER_00: It also does not show that a lower index means more renal blood flow.
- 4:45SPEAKER_00: The index is a downstream reading, not a measurement of flow.
- 4:49SPEAKER_01: Back to the comparison arm.
- 4:51SPEAKER_00: The conventional arm averaged about 80 millimeters of mercury, well above the guideline floor.
- 4:57SPEAKER_00: Part of the mortality gap, if it is real, could reflect how high the conventional arm ran.
- 5:02SPEAKER_00: The authors acknowledge this and call for a comparison against strict 65 to 70 targets.
- 5:08SPEAKER_00: Were the arms balanced?
- 5:10SPEAKER_00: Not where it counts, the article says.
- 5:12SPEAKER_00: More conventional arm patients had hypertension, 58.2% versus 46.3%,
- 5:18SPEAKER_00: and more were already on continuous renal replacement therapy at enrollment,
- 5:23SPEAKER_00: 13 versus 8 patients.
- 5:25SPEAKER_00: Both imbalances leaned toward the kidney outcomes the titration arm reported as better.
- 5:30SPEAKER_01: And the design?
- 5:32SPEAKER_00: A single center with unblinded clinicians.
- 5:34SPEAKER_00: So outcomes that depend on clinical decisions such as ventilator-free days are open
- 5:38SPEAKER_00: to performance bias.
- 5:40SPEAKER_00: After the first 120 patients,
- 5:42SPEAKER_00: the investigators reviewed the mortality they had observed and recalculated
- 5:46SPEAKER_00: that 268 were needed on an assumed reduction the authors themselves call optimistic.
- 5:52SPEAKER_00: The paper was also corrected on November 4, 2026,
- 5:56SPEAKER_00: and the article uses only the corrected values.
- 5:59SPEAKER_01: To the bedside.
- 6:00SPEAKER_01: The article's position is that kidney-guided titration is promising and is not
- 6:04SPEAKER_01: yet a standard of care.
- 6:06SPEAKER_00: For physicians and advanced practice providers, write 65 as a floor and justify anything higher.
- 6:12SPEAKER_00: Optpress is the reason a high fixed target needs a stated rationale in older patients.
- 6:17SPEAKER_00: For anyone scanning, Measure the index the way the trial did.
- 6:21SPEAKER_00: Let the map settle 5 to 10 minutes after each norepinephrine change.
- 6:25SPEAKER_00: Take three readings and average them.
- 6:27SPEAKER_00: Ignore changes smaller than 0.02.
- 6:31SPEAKER_01: Nurses and pharmacists?
- 6:33SPEAKER_00: For nurses, a titration protocol is nursing work.
- 6:36SPEAKER_00: Each step needs a dose change, a weight, and a repeat scan,
- 6:40SPEAKER_00: then 12 hours within 5 millimeters of mercury of target.
- 6:45SPEAKER_00: For pharmacists, watch the drug as well as the number.
- 6:48SPEAKER_00: Whenever a map target rises, track total vasopressor exposure and new arrhythmias.
- 6:54SPEAKER_00: And for everyone, cite the corrected version.
- 6:57SPEAKER_01: The teaching pearl?
- 6:58SPEAKER_00: A resistive index can show you where one kidney's pressure sweet spot sits.
- 7:03SPEAKER_00: Only patient outcomes can show you whether finding it matters.
- 7:07SPEAKER_00: And only a fair comparator can show you how much.
- 7:10SPEAKER_01: Personalizing the target is half of the trial.
- 7:13SPEAKER_01: The other half is what you compared it with.
- 7:16SPEAKER_01: What changed?
- 7:17SPEAKER_00: In this trial, using the kidney's Doppler signal
- 7:20SPEAKER_00: to choose each patient's MAP target was feasible at the bedside,
- 7:24SPEAKER_00: and it lowered the resistive index for at least 48 hours without more norepinephrine
- 7:30SPEAKER_00: and with fewer arrhythmias.
- 7:31SPEAKER_00: It did not significantly change 28-day mortality.
- 7:35SPEAKER_00: Keep 65 as the floor, avoid routine high-fix targets,
- 7:40SPEAKER_00: and treat kidney-guided titration as a hypothesis that has earned
- 7:44SPEAKER_00: a multi-center test against a strict 65 to 70 comparator.
- 7:49SPEAKER_01: The full article with the bedside takeaways by discipline and the five things not
- 7:53SPEAKER_01: to over-assume is on the ICCN substack.
- 7:56SPEAKER_01: The link is in the show notes.
- 7:58SPEAKER_01: ICCN publishes one article a day for ICU clinicians, $8 a month,
- 8:02SPEAKER_01: or $80 for the year, with a seven-day free trial.
- 8:05SPEAKER_01: This has been the ICCN Daily Brief.
- 8:07SPEAKER_01: Back tomorrow at 6.30.